Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 We wish to intimate that our wholly-owned subsidiary, Jubilant Pharma Limited ('Jubilant') has entered into a strategic partnership with SOFIE Biosciences, Inc. ('SOFIE'), USA. Under the terms of the partnership, Jubilant with 25% of equity holding shall be a strategic partner to SOFIE, enabling SOFIE to continue to grow production capacity, advance its theranostic pipeline, and support novel PET diagnostic manufacturing and distribution within the US.
04-11-2020
Bigul

Jubilant Life Sciences Sept quarter net profit declines 10% to Rs 224 crore

 Drug firm Jubilant Life Sciences on Wednesday reported a 10.13 per centdecline in its consolidated net profit to Rs 224.12 crore for the quarter ended September,mainly on account of higher taxes. The company had posted a net profit of Rs 249.39 crore for the correspondingperiod of the previous fiscal, Jubilant Life Sciences said in a BSE filing. Total revenue from operations stood at Rs 2,374.89 crore for the quarter under consideration. It was Rs 2,265.93 crore for the same period a year ago, it added. Tax expense of the company for the quarter was Rs 89.55 crore as against Rs 42.84 crore for the same period of the previous fiscal, the filing said. "Q2'FY21 has witnessed a substantial improvement over the previous quarter despite continued adverse impact of the COVID-19 pandemic in at least the first half of Q2,"Jubilant Life SciencesChairmanShyam S Bhartia andCo-Chairman & MD Hari S Bhartia said. With the strong demand recovery and new business sign-ups, "we expect strong...
04-11-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Raising of Funds

 Pursuant to the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today, approved issuance of Secured Unlisted Non-Convertible Debentures (NCDs) upto an amount of Rs. 100 Crore on private placement basis. The Board meeting commenced at 1.00 p.m. and concluded at 3:15 p.m. We request you to take the same on record.
04-11-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Results For The Quarter Ended September 30, 2020

 Results for the quarter ended September 30, 2020
04-11-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Credit Rating

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that India Ratings and Research Private Limited has maintained Long-term issuer rating of 'IND AA'/Rating Watch Evolving (RWE) for Jubilant Life Sciences Limited.
31-10-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation of our letter dated October 28, 2020, we enclose copies of the advertisements published on October 29, 2020, in MINT (English) and HINDUSTAN (Hindi) with respect to notice of the Board Meeting scheduled to be held on November 4, 2020.
29-10-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Schedule Of Investor Conference Call For Jubilant Life Sciences Limited - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2020

 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on Wednesday, November 4, 2020 after submission of the financial results for the quarter and half year ended September 30, 2020 to the Stock Exchanges. Details of the Conference Call are attached.
28-10-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Board Meeting Intimation for Intimation Of Board Meeting - November 4, 2020

 JUBILANT LIFE SCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2020 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, November 4, 2020, to inter-alia consider: 1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2020. 2. The proposal to issue Non-Convertible Debentures upto Rs. 100 Crore.
28-10-2020
Bigul

Jubilant Life Sciences Ltd - 530019 - Shareholding for the Period Ended September 30, 2020

 Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here
20-10-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Certificate Under Regulation 40(9) And Regulation 40(10) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

 As per Regulation 40(9) and Regulation 40(10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a Certificate obtained from a Practising Company Secretary for the period ended September 30, 2020.
16-10-2020
Next Page
Close

Let's Open Free Demat Account